Nurix Therapeutics Inc.

Nurix Therapeutics Inc.

World Rank (Aug-2026)
5235
Market Cap (Aug-2026)
2.807 Billion USD
Market Cap (Mar-08-2026)
1.553 Billion USD
World Rank (Jan-05-2024)
12,883
Market Cap (Jan-05-2024)
0.478 Billion USD
World Rank (Jul-30-2023)
13,148
Market Cap (Jul-30-2023)
0.469 Billion USD
World Rank (Jan-07-2022)
8,355
Market Cap (Jan-07-2022)
1.234 Billion USD
World Rank (Jan-01-2021)
6,970
Market Cap (Jan-01-2021)
1.278 Billion USD
Headquarters Country
USA
Nasdaq / NYSE Code
NRIX
Employee Count
242
Employee Count as of Date
As on 2021
Headquarters City/State
California
World Region
Americas
World Subregion
Northern America
Annual Revenue in USD
84 Million USD
Annual Operating Income in USD
-286 Million USD
Annual Net Income in USD
-264 Million USD
Annual Results for Period Ending
For year ending November-2025
Total Assets in USD
688 Million USD
Total Liabilities in USD
149 Million USD
Total Equity in USD
539 Million USD
Balance Sheet for Period Ending
As of November-2025
Business Sector
Healthcare
Biotechnology
Biopharmaceutical
Company Website
NURIX THERAPEUTICS, INC.
Yahoo
Yahoo @ Nasdaq
Company Profile
Nurix Therapeutics is a  Biopharmaceutical company discovers drugs that harness the bodies natural process to control protein levels and drugs control ubiquitin E3 ligases, the key enzymes responsible for protein breakdown in human cells as a unique therapeutic approach to treat a broad range of diseases. The company annual revenue is 17.8 million USD and 103 employees as on 2019. The headquarters is in USA.
IPO Year
2020
Stock Exchange
Nasdaq
Nasdaq Sector
Health Care
Nasdaq Industry
Biotechnology: Pharmaceutical Preparations

Share